An evaluation of the cardiovascular safety profile of duloxetine: Findings from 42 placebo-controlled studies

Drug Safety

Volumn 30, Issue 5, 2007, Pages 437-455

  Wernicke, Joachim ^a   Lledó, Alberto ^a   Raskin, Joel ^a   Kajdasz, Daniel K ^a   Wang, Fujun ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; ATRIOVENTRICULAR BLOCK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; INCIDENCE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROPATHIC PAIN; ORTHOSTATIC HYPERTENSION; PERIPHERAL EDEMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RR INTERVAL; SIDE EFFECT; SWELLING; SYNCOPE; TACHYCARDIA; VARICOSIS; VASCULAR DISEASE;

ADRENERGIC UPTAKE INHIBITORS; ANXIETY DISORDERS; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER, MAJOR; DIABETIC NEUROPATHIES; FIBROMYALGIA; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; URINARY INCONTINENCE;

EID: 34248329070     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730050-00007     Document Type: Article

References (75)

1. Stage KB, Danish University Antidepressant Group. Orthostatic side effects of clomipramine and moclobemide during treatment for depression. Nord J Psychiatry 2005; 59: 298-301
2. Glassman AH, Bigger JJ, Giardina EV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979; I: 468-72
3. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991; 325: 633-42
4. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308-15
5. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383-90
6. Goldstein DJ, Lu Y, Detke M, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-99
7. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63: 225-31
8. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9: 29-40
9. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-56
10. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18
11. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187: 40-8
12. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004; 111: 249-57
13. Millard RJ, Moore K, Rencken R, et al. Duloxetine vs. placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004; 93: 311-8
14. Detke M, Iyengar S, Henck JW, et al. Cardiovascular effects of duloxetine: preclinical and clinical findings. American College of Neuropsychopharmacology 44th Annual Meeting; 2005 Dec 11-15; Waikoloa (HI)
15. Data on file, Eli Lilly and Company, 2006
16. Data on file, Eli Lilly and Company, 2006
17. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at therapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 2007; 49: 146-53
18. Derby MA, Zhang L, Chappell J, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol. In Press
19. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237-44
20. Wernicke JF, Raskin J, Rosen A, et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: an open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res 2006; 67: 283-304
21. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. In Press
22. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106-32
23. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14: 457-70
24. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 21: 367-78
25. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. In Press
26. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39: 43-53
27. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepresant action, a non-inferiority study. Curr Med Res Opin 2007; 23: 401-16
28. Mundt JC, DeBrota DJ, Greist, JH. Anchoring perceptions of clinical change on accurate recollection of the past: Memory Enhanced Retrospective Evaluation of Treatment (MERET® ). Psychiatry 2007; 4: 39-45
29. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-20
30. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: Implications for primary care physicians. Primary Care Companion J Clin Psychiatry. In Press
31. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. In Press
32. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo-and active-controlled trial. Int Clin Psychopharmacol. In Press
33. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-84
34. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15
35. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005; 173: 1647-53
36. Cardozo L, Drutz HP, Baygani SK, et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004; 104: 511-9
37. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003; 170 (4 Pt 1): 1259-63
38. Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 337-44
39. Castro-Diaz D, Palma PCR, Bouchard C, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J. In Press
40. Mah SY, Lee KS, Choo MS, et al. Duloxetine versus placebo for the treatment of Korean women with stress predominant urinary incontinence. Korean J Urol 2006; 47: 527-35
41. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 Suppl. 1: S39-45
42. Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000; 140 Suppl.: 84-8
43. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Design 2004; 10: 2463-75
44. Vohra J, Burrows G, Hunt D, et al. The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intra-cardiac conduction. Eur J Cardiol 1975; 3: 219-27
45. Giardina EG, Bigger JT Jr, Glassman AH, et al. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 1979; 60: 1045-52
46. Glassman AH, Bigger JT Jr, Giardina EV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979; I: 468-72
47. Sala M, Coppa F, Cappucciati C, et al. Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes. Curr Opin Investig Drugs 2006; 7: 256-63
48. Pacher P, Ungvari Z, Kecskemeti V, et al. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr Med Chem 1998; 5: 381-90
49. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Ann Rev Med 1984; 35: 503-11
50. Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on differences between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects: is there any? Curr Med Chem 1999; 6: 469-80
51. Burckhardt D, Raeder E, Muller V, et al. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978; 239: 213-6
52. Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981; 38: 815-20
53. Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19: 407-15
54. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Rev Psychiatr Neurosci 2006; 31: 122-31
55. Enemark B. The importance of ECG monitoring in antidepressant treatment. Nord J Psychiatry 1993; 47 Suppl. 30: 57-65
56. Cherin P, Colvez A, Deville de Periere G, et al. Risk of syncope in the elderly and consumption of drugs: a case-control study. Clin Epidemiol 1997; 50: 313-20
57. Fuller RW, Holland DR, Yen TT, et al. Antihypertensive effects of fluoxetine and L-5-hydroxytryptophan in rats. Life Sci 1979; 25: 1237-42
58. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396-404
59. Stahl SM, Grady MM, Moret C, et al. SNRIs: The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10: 732-47
60. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234-41
61. Tran PV, Bymaster FP, McNamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23: 78-86
62. Hirschfeld R, Mallinckrodt C, Prakash A, et al. Efficacy of duloxetine versus combined SSRIs (fluoxetine, paroxetine, escitalopram) and placebo in the treatment of major depressive disorder [abstract]. American Psychiatric Association Annual Conference; 2006 May 20-25; Toronto (ON)
63. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl. 1: 11-7
64. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-99
65. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986; 90: 131-8
66. Cipriani A, Brambilla P, Furakawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005; 4: CD004185
67. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59: 502-8
68. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28-34
69. Katona C, Bercoff E, Chiu E, et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomized trial. J Affect Disord 1999; 55: 203-13
70. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-80
71. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005; 25: 132-40
72. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-9
73. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999; 291: 280-4
74. Detke MJ, Iyengar S, Henck JW, et al. Cardiovascular effects of duloxetine: preclinical and clinical findings. Neuropsychopharmacol 2005; 30 Suppl. 1: 5105-6
75. Luo S, Michler K, Johnston P, et al. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004; 37 Suppl.: 81-90